1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Merck Jumps Into Lucrative Adjuvant NSCLC Space With Keytruda Data

 
• By Alaric DeArment
lung illustration
Merck announced Phase III interim data for Keytruda in adjuvant NSCLC • Source: Shutterstock

Merck & Co., Inc. is jumping into the potentially lucrative market of adjuvant treatment of non-small cell lung cancer (NSCLC) with new Phase III data for Keytruda (pembrolizumab) that sets the PD-1 inhibitor up as a competitor to Roche Holding AG’s PD-L1 inhibitor, Tecentriq (atezolizumab). However, there is some question about how closely the two drugs will compete based on the magnitude of Keytruda’s benefit in patients with high PD-L1 expression, despite the drug’s efficacy in a broader range of patients.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Amgen’s Imdelltra Sets The Pace In Small-Cell Lung Cancer

 
• By Andrew McConaghie

The bispecific is the first in its class to record a Phase III survival win in small-cell lung cancer, although antibody-drug conjugates and other rivals could challenge in the coming years.

Scancell Signs UK Match-Making Pact For Melanoma Vaccine

 
• By Kevin Grogan

The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.

Bristol’s Opdivo + Yervoy Gets FDA Liver, Colorectal Cancer Nods

 
• By Joseph Haas

Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.

Novartis $23bn US Investment Is Music To Trump’s Ears

 
• By Kevin Grogan

The Swiss major follows Lilly and J&J in committing to a significant spend on US manufacturing.

More from Therapy Areas

Pfizer’s Danuglipron Is Done, Sparking M&A Speculation

 
• By Jessica Merrill

The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.

Amgen’s Imdelltra Sets The Pace In Small-Cell Lung Cancer

 
• By Andrew McConaghie

The bispecific is the first in its class to record a Phase III survival win in small-cell lung cancer, although antibody-drug conjugates and other rivals could challenge in the coming years.

Scancell Signs UK Match-Making Pact For Melanoma Vaccine

 
• By Kevin Grogan

The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.